This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method formeasuring indirect costs of disease. J Health Econ. 1995;14:171–89.
Brouwer WBF, Koopsmanschap MA, Rutten FH. Productivity costs in cost effectiveness analysis: numerator or denominator? A further discussion. Health Econ. 1997;6:511–4.
Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. PharmacoEconomics. 2006;24(1):43–53.
Brouwer WBF. Too important to ignore: informal care givers and significant others. PharmacoEconomics. 2006;24(1):39–41.
Rappange DR, van Baal PHM, van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. Unrelated medical costs in life years gained: should they be included in economic evaluations of health care interventions? PharmacoEconomics. 2008;26(10):815–6.
Bobinac A, Van Exel J, Rutten F, Brouwer W. Caring for and caring about: disentangling the caregiving effect and the family effect. J Health Econ. 2010;29:549–56.
Wittenberg E, Prosser L. Disutility of Illness for caregivers and families: a systematic review of the literature. PharmacoEconomics. 2013;31(6):489–500.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for the conduct, methodological practices, and reporting of cost effectiveness analyses: Second panel on cost effectiveness in medicine and health. JAMA. 2016;316(10):1093–103.
Canadian Agency for Drugs and Technology in Health Care Common Drug Review. https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr. Accessed 31 July 2018.
NICE Technology Appraisal Guidance. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance. Accessed 31 July 2018.
Australian Government Department of Health. Pharmaceutical Benefits Advisory Committee. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings. Accessed 31 July 2018.
Paulden M, O’Mahoney J, McCabe C. Determinants of change in the cost effectiveness threshold. Med Decis Making. 2017;37:264–76.
Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberations and the legitimacy problem for insurers. Philos Public Aff. 1997;26(4):303–50.
Tudor-Hart J. The inverse care law. Lancet. 1971;297:405–12.
Charles G, Stainton T, Marshall S. Young carers in Canada: the hidden costs and benefits of young caregiving. Vanier Institute of the Family, 2012 Vancouver. http://vanierinstitute.ca/wp-content/uploads/2015/12/CFT_2012-07-00_EN.pdf. Accessed 30 July 2018.
Cookson R, Mirelman AJ, Griffin S, et al. Using cost effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206–12.
Lavalle TA, Wittenberg E, Lamarand K, Prosser LA. Variation in the spillover effects of illness on parents, spouses and children of the chronically ill. Appl Health Econ Health Policy. 2014;12(2):117–24.
Brouwer W. The inclusion of spillover effects in economic evaluation: not an optional extra. PharmacoEconomics. 2018. https://doi.org/10.1007/s40273-018-0719-1
Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2017. https://doi.org/10.1002/hec.3633.
Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2017. https://doi.org/10.1007/s40273-017-0585-2 (accessed 30 July 2018).
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1–503 (v–vi).
Lomas J, Claxton K, Martin S, Soares M. Resolving the “Cost-Effective but Unaffordable” Paradox: estimating the health opportunity costs of nonmarginal budget impacts. Value Health. 2018. https://doi.org/10.1016/j.jval.2017.10.006 (accessed 31 July 2018).
Global Genes: FDA Orphan Drug Approvals 2018. https://globalgenes.org/raredaily/181474-2/. Accessed 31 July 2018.
Ebied AM, Cooper-deHoff RM. 2017 Banner Year for Drug Approvals. Am Med J. 2018. https://www.sciencedirect.com/science/article/pii/S0002934318302882. Accessed 31st July 2018 (in press).
Al-Janabi H, van Exel J, Brouwer W, Coast J. A framework for including family health spillovers in economic evaluation. Med Decis Mak. 2016;36(2):176–86.
Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ. 2015;24(1):1–7.
No sources of funding were used to prepare this commentary.
Conflict of interest
Christopher McCabe has no conflicts of interest that are directly relevant to the content of this commentary.
About this article
Cite this article
McCabe, C. Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution. PharmacoEconomics 37, 457–460 (2019). https://doi.org/10.1007/s40273-018-0729-z